A phase 2 study of bortezomib in relapsed, refractory myeloma.

Keywords

Medicine, Bortezomib, Multiple myeloma, Neutropenia, Internal medicine

References

• Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B.Dharminder Chauhan, Hiroshi Uchiyama, Yasmin Akbarali — 1996
• Survival analysis using the SAS system : a practical guidePaul D. Allison — 1995
• Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341.A Frankel, Si Ming Man, Peter J. Elliott — 2000
• NF-kappa B as a therapeutic target in multiple myeloma.Teru Hideshima, Dharminder Chauhan, Paul G. Richardson — 2002
• Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation.Klaus Podar, Yu‐Tzu Tai, Boris K. Lin — 2002
• In vivo ubiquitination and proteasome-mediated degradation of p53(1).Carl G. Maki, J M Huibregtse, Peter M. Howley — 1996
• Molecular mechanisms of novel therapeutic approaches for multiple myelomaTeru Hideshima, Kenneth C. Anderson — 2002
• CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONJoan Bladé, Diana Samson, Donna Reece — 1998
• Molecular sequelae of proteasome inhibition in human multiple myeloma cellsNicholas Mitsiades, Constantine Mitsiades, Vassiliki Poulaki — 2002
• Cut8, essential for anaphase, controls localization of 26S proteasome, facilitating destruction of cyclin and Cut2.Hisashi Tatebe, Mitsuhiro Yanagida — 2000
• Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implicationsConstantine S. Mitsiades, Nicholas Mitsiades, Vassiliki Poulaki — 2002
• Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.Suzanne Russo, Joel E. Tepper, Albert S. Baldwin — 2001
• Phase III Study Comparing Vincristine, Doxorubicin (Adriamycin), and Dexamethasone (VAD) Chemotherapy with VAD Plus Recombinant Interferon Alfa‐2 in Refractory or Relapsed Multiple Myeloma: An Eastern Cooperative Oncology Group StudyLeslie A. Kalish, Robert A. Kyle, Richard G. Hahn — 1995
• Proteasome inhibitors: from research tools to drug candidates.Alexei F. Kisselev, Alfred L. Goldberg — 2001
• The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications.Teru Hideshima, Dharminder Chauhan, Robert Schlossman — 2001
• 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancerShimul A. Shah, Michael W. Potter, Theodore P. McDade — 2001
• Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome.Richard J. Bold, Subbulakshi Virudachalam, David J. McConkey — 2001
• Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27.Michele Pagano, Sun W. Tam, Anne M. Theodoras — 1995
• Treatment Approaches for Relapsing and Refractory Multiple MyelomaJordi Esteve Joan Bladé — 2000
• Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.John B. Sunwoo, Zhong Chen, Guo‐Chung Dong — 2001

Cited by

• Investigation of the intrinsic mechanism of drug resistance in multiple myelomaMelissa Ooi — 2011
• Cost effectiveness of bortezomib in the treatment of advanced multiple myeloma.Jayesh Mehta, Steven B. Duff, Sanjay Gupta — 2004
• Proteasome Inhibitor Bortezomib Enhances the Activity of Multiple Mutant Forms of Lysosomal α-Glucosidase in Pompe Disease.Yohta Shimada, Erica Nishimura, Hiroo Hoshina — 2015
• Interruption of the NF-kappaB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells.Tomás Llorens Serra — 2004
• Pancreatic Cancer Experimental and Clinical StudiesDavid Ljungman — 2013
• Transforming Growth Factor β Receptor I Kinase Inhibitor Down-Regulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow MicroenvironmentElsa Plaza Müller — 2004
• Morphoproteomics: exposing protein circuitries in tumors to identify potential therapeutic targets in cancer patientsRaúl Diego Obregón — 2005
• Sulindac Enhances the Proteasome Inhibitor Bortezomib-Mediated Oxidative Stress and Anticancer Activity好孝 桑原, 善則 管野, 和夫 鈴木 — 2005
• The ubiquitin-proteasome pathway and its role in cancer.浩己 藤田, 照和 西嵜, 昌孝 前田 — 2005
• Toxic neuropathySusan Ariew — 2005
• Advances in the management of myeloma bone diseaseI. Popov, A. A. Rukhadze — 2005
• Risk stratification of patients with newly diagnosed multiple myeloma: optimizing treatment based on pretreatment characteristics.Jian Chen, Qingkang Wang, Haihua Li — 2005
• Overview of drug therapy for multiple myelomaGeoff Saunders — 2005
• Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice.Jinshan Li, Yu Xia — 2007
• Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cellsJulio del Valle — 2007
• Review of peripheral neuropathy in plasma cell disordersG.W. Parker, William Joseph Martin, G.E. Creek — 2008
• Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma.David E. Fernie — 2008
• Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.Henrique Ortêncio Filho, W. H. Robinson, A. E. de Carvalho Campos — 2008
• Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myelomaElisenda Ibañez Herrero, Ignacio José De Costa González — 2009
• Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment.Joan Bladé, Pieter Sonneveld, Jesús F. San Miguel — 2008

Related papers

• Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myelomaM. Wang, Sergio Giralt, Kay Delasalle — 2007
• Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myelomaTaleb Azarm, Mojtaba Akbari, Arezo Azarm — 2012
• Rapid control of previously untreated multiple myeloma with bortezomib–lenalidomide–dexamethasone (BLD)M. Wang, Kay Delasalle, Sergio Giralt — 2010
• Hematology: Setting the standard for newly diagnosed multiple myelomaJacob P. Laubach, Paul G. Richardson, Kenneth C. Anderson — 2011
• Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myelomaDan T. Vogl, Edward A. Stadtmauer, Paul G. Richardson — 2009
• Bortezomib for the treatment of multiple myelomaSebastian Grosicki, Agnieszka Barchnicka, Artur Jurczyszyn — 2014
• Efficacy of Low-dosage Bortezomib Combination with Dexamethasone,THP and Thalidomide for Multiple MyelomaWang Ju — 2014
• Activity of panobinostat in combination with bortezomib and dexamethasone in advanced, proteasome inhibitor refractory multiple myelomaBranka Petričević, Wolfgang Hilbe, Niklas Zojer — 2017